{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:32Z","timestamp":1793499992903,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); however, severe immune effector cell\u2013associated adverse events, including cytokine release syndrome (CRS) and neurotoxicity, remain major clinical challenges. We investigated whether the platelet-to-lymphocyte ratio (PLR) could serve as a predictive biomarker for severe toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, 15 patients with relapsed or refractory DLBCL treated with tisagenlecleucel were analyzed. PLR was measured prior to lymphodepletion. Receiver operating characteristic (ROC) analysis was performed to determine the optimal PLR cutoff for predicting severe immune-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The optimal PLR cutoff was 198, with a sensitivity of 85.7% and a specificity of 87.5%. Patients with higher baseline PLR values had a significantly higher incidence of severe adverse events compared with those with lower PLR values (85.7% vs. 12.5%). Baseline PLR was positively correlated with post-infusion increases in serum ferritin, a surrogate marker of systemic inflammation. Compared with other inflammatory biomarkers, PLR demonstrated an intermediate sensitivity\u2013specificity trade-off.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline PLR may represent a simple and accessible biomarker associated with an increased risk of severe immune-related toxicities following CAR T-cell therapy. These findings support its potential role in pre-infusion risk stratification, although validation in larger cohorts is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1731711","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:03:46Z","timestamp":1774368226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Changgon","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunye","family":"Kwak","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Won","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Seok","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine","place":["Seoul, Republic of Korea"]},{"name":"Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023177","article-title":"Recent advances in cellular immunotherapy for lymphoid Malignancies","volume":"58","author":"Chung","year":"2023","journal-title":"Blood Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023026","article-title":"Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy","volume":"58","author":"Yoo","year":"2023","journal-title":"Blood Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1367990","article-title":"Prognostic relevance of platelet lymphocyte ratio (PLR) in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Hou","year":"2024","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12957-025-03838-7","article-title":"Prognostic value of platelet to lymphocyte ratio in patients with cervical cancer: an updated systematic review and meta-analysis","volume":"23","author":"Zhu","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2019.39.4.345","article-title":"The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases","volume":"39","author":"Gasparyan","year":"2019","journal-title":"Ann Lab Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27297","article-title":"Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis","volume":"94","author":"Sarkar","year":"2022","journal-title":"J Med Virol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02612-3","article-title":"Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma","volume":"60","author":"Goel","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000522307","article-title":"Tocilizumab treatment effect on iron homeostasis in severe COVID-19 patients","volume":"145","author":"Guz","year":"2022","journal-title":"Acta Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu Rev Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbj.2017.05.005","article-title":"Role of platelets in immune system and inflammation","volume":"2","author":"Sonmez","year":"2017","journal-title":"Porto BioMed J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.302700","article-title":"Interleukin 1 receptor 1 and interleukin 1\u03b2 regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans","volume":"34","author":"Beaulieu","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.3390\/ijms22084152","article-title":"Lymphopenia, lymphopenia-induced proliferation, and autoimmunity","volume":"22","author":"Sheu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.imlet.2004.10.022","article-title":"A causal link between lymphopenia and autoimmunity","volume":"98","author":"Khoruts","year":"2005","journal-title":"Immunol Lett"},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/bloodadvances.2024014125","article-title":"Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma","volume":"9","author":"Ferri","year":"2025","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.3390\/jcm11164903","article-title":"Platelet-to-lymphocyte ratio (PLR) is not a predicting marker of severity but of mortality in COVID-19 patients admitted to the emergency department: A retrospective multicenter study","volume":"11","author":"Simon","year":"2022","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023015","article-title":"Practical issues in CAR T-cell therapy","volume":"58","author":"Byun","year":"2023","journal-title":"Blood Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:03:47Z","timestamp":1774368227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1731711"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1731711","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"1731711"}}